BxLink

BxLink is a digital pathology platform developed by Lumea, designed for pathology practices and laboratories that are ready to adopt digital pathology but do not currently have a laboratory information system (LIS) or do not wish to replace an existing one. It is available in two versions — BxLink and BxLink-Lite — and combines LIS functionality with digital pathology tools in a single platform.

The platform covers billing, slide orders, second opinions, primary diagnosis, preliminary reporting, and ancillary test management, positioning itself as an all-in-one solution for pathology workflows. BxLink also integrates with electronic medical record (EMR) systems and supports AI algorithms for diagnostic assistance.

Core Platform Capabilities

• Combines a laboratory information system (LIS) and digital pathology suite in a single platform.
• Supports billing, slide orders, second opinions, primary diagnosis, and preliminary reporting.
• Tracks biopsy procedures to help laboratories stay organized.
• Replaces paper lab requisitions with digital alternatives.

Workflow and Histology Features

• Creates pathology work lists to organize case review.
• Supports histology workflow using advanced consumables and software tools.
• Provides end-to-end, chain-of-custody RFID specimen tracking to maintain specimen integrity throughout the process.

Integration and Data Management

• Integrates with any EMR system to support report retrieval and information sharing.
• Supports data and storage management for research use cases.
• Incorporates AI algorithms for pathology analysis.

Ancillary Test Process

• Allows digital ordering of ancillary tests directly within BxLink, replacing paper requisitions.
• Automates test result integration into the EMR, with a reported 53% faster turnaround time.
• Supports customizable conditional test orders based on procedure type and diagnosis.

BxLink is developed by Lumea, headquartered in Lehi, Utah. The platform is noted as scalable for individual pathologists as well as larger practices. BxLink has not been approved by the FDA for digital primary diagnosis; users are directed to refer to CAP guidelines regarding the use of digital pathology technologies.